Neogemodez is prescribed in the following cases: detoxification of the body in infectious diseases accompanied by toxicosis; burn disease in the intoxication phase (2 – 5th day); acute radiation sickness in the intoxication phase; peritonitis and intestinal obstruction (in the pre- and postoperative period); acute renal failure of various etiologies; thyrotoxicosis; sepsis; liver disease in the phase of liver failure.
The main active substances: 1 liter of solution contains povidone (plasdon S-15) 60 g, sodium chloride 5.5 g, potassium chloride 0.42 g, calcium chloride hexahydrate 0.5 g, magnesium chloride hexahydrate 0.005 g, sodium bicarbonate 0, 23 g
Excipients: water for injection.
Solution for infusion, volume 200 ml in vials.
Neogemodez is a blood substitute and perfusion solution.
The effectiveness of the drug is determined by the fact that low molecular weight polyvinylpyrrolidone binds toxins in the blood and quickly removes them from the body. The maximum activity of the active substance is observed relative to toxins circulating in the blood during dysentery, salmonellosis, food intoxication. The inactivation of the toxins formed during a burn disease in the first 4-5 days of the disease occurs almost completely.
In acute radiation sickness, the binding of toxins does not occur, but they are eliminated faster. The use of the drug improves microcirculation in blood vessels.
There is also an increase in renal blood flow, an increase in glomerular filtration and an increase in urine output.
Neogemodez is prescribed in the following cases:
- detoxification of the body in infectious diseases accompanied by toxicosis;
- burn disease in the intoxication phase (2 – 5th day);
- acute radiation sickness in the intoxication phase;
- peritonitis and intestinal obstruction (in the pre- and postoperative period);
- acute renal failure of various etiologies;
- liver disease in the phase of liver failure.
The drug in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or one of the auxiliary components.
The drug is contraindicated in the following cases:
- severe cardiovascular and pulmonary insufficiency;
- hemorrhagic stroke;
- bronchial asthma;
- sharp nephritis;
- severe allergic and immunosuppressive conditions.
In pediatrics, the drug is used after 6 years.
Application during pregnancy and lactation
Neogemodez is not allowed to be used by pregnant women – only under strict indications determined by the attending physician.
If it is necessary to take the drug during breastfeeding, lactation is suspended.
Method of administration and dosage
Neogemodez is injected intravenously at a rate of 20-40 drops per minute. Before the introduction, the solution is heated to 35 – 37 ° C.
A single dose for adults is 400 ml, for children 6 – 9 years old – up to 100 ml; for children 10 – 15 years old – up to 150 ml. Repeated infusions of the drug are carried out according to indications, but not earlier than 10 – 12 hours after its previous administration. The course of treatment is no more than 5 days.
The introduction of the drug, especially in severe conditions, must be carried out under the supervision of a physician.
In case of an overdose, the following may occur:
- arterial hypotension.
The drug is usually well tolerated when used in the recommended doses.
The following disorders can be observed as side effects:
- anaphylactic shock, angioedema, hyperthermia;
- pallor of the skin, skin rash, urticaria, hyperemia, maculopapular and petechial rash, pruritus;
- tachycardia, pain in the region of the heart, arterial hypotension;
- shortness of breath, bronchospasm;
- headache, dizziness;
- nausea, vomiting;
- general weakness, sweating, fever with chills.
Storage conditions and periods
Expiration date – up to 5 years from the production date indicated on the package. Storage periods should not be exceeded.
Storage temperature should not exceed 25 ° C. Temperature deviations can change the properties of the preparation, therefore it should always be stored in its original packaging.